Background: Cancer-related financial hardship is associated with poor care outcomes and reduced quality of life for patients and families. Scalable intervention development to address financial hardship requires knowledge of current screening practices and services within community cancer care. Methods: The NCI Community Oncology Research Program (NCORP) 2017 Landscape Assessment survey assessed financial screening and financial navigation practices within U.S. community oncology practices. Logistic models evaluated associations between financial hardship screening and availability of a cancer-specific financial navigator and practice group characteristics (e.g., safetynet designation, critical access hospital, proportion of racial and ethnic minority patients served). Results: Of 221 participating NCORP practice groups, 72% reported a financial screening process and 50% had a cancerspecific financial navigator. Practice groups with more than 10% of new patients with cancer enrolled in Medicaid (adjOR = 2.81, P = 0.02) and with less than 30% racial/ethnic minority cancer patient composition (adjOR = 3.91, P < 0.01) were more likely to screen for financial concerns. Practice groups with less than 30% racial/ethnic minority cancer patient composition (adjOR = 2.37, P < 0.01) were more likely to have a dedicated financial navigator or counselor for patients with cancer. Conclusions: Most NCORP practice groups screen for financial concerns and half have a cancer-specific financial navigator. Practices serving more racial or ethnic minority patients are less likely to screen and have a designated financial navigator. Impact: The effectiveness of financial screening and navigation for mitigating financial hardship could be tested within NCORP, along with specific interventions to address cancer care inequities.
|Number of pages||7|
|Journal||Cancer Epidemiology Biomarkers and Prevention|
|State||Published - Apr 2021|
Bibliographical noteFunding Information:
This work was funded by the NCI of the NIH through the NCI Community Oncology Research Program (NCORP), including Awards 1UG1 CA189824 (Wake Forest Health Sciences NCORP Grant; C.L. Nightingale, E.V. Dressler, A.C. Snavely, K.E. Weaver; PI: G. Lesser), 2UG1 CA189828 (ECOG-ACRIN NCORP Research Base; R. Carlos; PI: P. O'Dwyer), 2UG1 CA189867-07 (NRG Oncology, M.F. Hudson; PI: D. Bruner), UG1 CA189972 (NCORP of the Carolinas, M.F. Hudson; PI:
L.E. McLouth reported grants from NIH/NCI during the conduct of the study. C.L. Nightingale reported grants from NIH/NCI during the conduct of the study. E.V. Dressler reported grants from NIH/NCI during the conduct of the study; grants from Omada Health, NIH/NCI, DoD, and NHLBI outside the submitted work. A.C. Snavely reported grants from NIH/NCI during the conduct of the study; grants and personal fees from Shattuck Labs outside the submitted work. M.F. Hudson reported funding through a grant from the NCI-National Community Oncology Research Program Funding Number UCA189972B (NCORP of the Carolinas); UG1CA189867 NRG Oncology Research Base). R. Carlos reported grants from NCI during the conduct of the study; salary support as editor from Journal of the American College of Radiology outside the submitted work. C.S. Kamen reported grants from NCI during the conduct of the study. K.E. Weaver reported grants from NIH/NCI during the conduct of the study. No other disclosures were reported.
K. Chung), and UG1 CA189961 (C.S. Kamen; PI: Morrow). L.E. McLouth’s work on this article was supported by R25 CA122061 (PI: N. Avis) and P30 CA177558 (PI: B. Evers). C.L. Nightingale’s work on this article was supported by the National Center for Advancing Translational Sciences (NCATS), and NIH (UL1TR001420; PI: D. McClain; KL2TR001421-06; PI: D. Miller). S.J.C. Lee’s work was supported by P30 CA142543 (PI: C. Arteaga).
© 2021 American Association for Cancer Research.
ASJC Scopus subject areas